REBECCA KREPS: Open Payments
NPI 1033112404 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$785 in 33 payments from 8 companies in 2025. Trend: 2023 $702 · 2024 $715 · 2025 $785
Food & beverage: $686Education: $99
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $283 |
| MAYNE PHARMA COMMERCIAL LLC | 9 | $156 |
| Sage Therapeutics, LLC | 5 | $121 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $99 |
| Supernus Pharmaceuticals, Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Organon LLC | 2 | $27 |
| Amgen Inc. | 1 | $18 |
Products named: Veozah, ZURZUVAE, Mirena, Qelbree, Lynkuet, NEXPLANON, GEMTESA, EVENITY.
Industry payments across MD — which companies pay providers there.
